SG11201907271PA - Proteins binding psma, nkg2d and cd16 - Google Patents

Proteins binding psma, nkg2d and cd16

Info

Publication number
SG11201907271PA
SG11201907271PA SG11201907271PA SG11201907271PA SG11201907271PA SG 11201907271P A SG11201907271P A SG 11201907271PA SG 11201907271P A SG11201907271P A SG 11201907271PA SG 11201907271P A SG11201907271P A SG 11201907271PA SG 11201907271P A SG11201907271P A SG 11201907271PA
Authority
SG
Singapore
Prior art keywords
international
lebanon
lucent
nkg2d
pct
Prior art date
Application number
SG11201907271PA
Other languages
English (en)
Inventor
Gregory Chang
Ann Cheung
William Haney
Bradley Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of SG11201907271PA publication Critical patent/SG11201907271PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201907271PA 2017-02-10 2018-02-10 Proteins binding psma, nkg2d and cd16 SG11201907271PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762457785P 2017-02-10 2017-02-10
PCT/US2018/017718 WO2018148610A1 (en) 2017-02-10 2018-02-10 Proteins binding psma, nkg2d and cd16

Publications (1)

Publication Number Publication Date
SG11201907271PA true SG11201907271PA (en) 2019-09-27

Family

ID=63107819

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907271PA SG11201907271PA (en) 2017-02-10 2018-02-10 Proteins binding psma, nkg2d and cd16

Country Status (13)

Country Link
US (1) US20200024353A1 (ko)
EP (1) EP3579878A4 (ko)
JP (2) JP2020507577A (ko)
KR (1) KR20190120770A (ko)
CN (1) CN110913902A (ko)
AU (1) AU2018217834A1 (ko)
BR (1) BR112019016553A2 (ko)
CA (1) CA3053275A1 (ko)
IL (1) IL268574A (ko)
MX (1) MX2019009541A (ko)
RU (1) RU2019128204A (ko)
SG (1) SG11201907271PA (ko)
WO (1) WO2018148610A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221995A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
JP2021512630A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン
WO2023011431A1 (zh) * 2021-08-03 2023-02-09 江苏先声药业有限公司 一种cd16抗体及其应用
WO2023011650A1 (zh) * 2021-08-06 2023-02-09 甘李药业股份有限公司 一种多特异性抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300919A2 (hu) * 2000-03-24 2003-07-28 Micromet Ag Többfunkciós polipeptidek NKG2D receptor komplex epitóp kötőhellyel
US6455712B1 (en) * 2000-12-13 2002-09-24 Shell Oil Company Preparation of oxirane compounds
EP1909832A4 (en) * 2005-06-29 2010-01-13 Univ Miami ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY
AU2006338562A1 (en) * 2005-11-03 2007-08-30 Genentech, Inc. Therapeutic anti-HER2 antibody fusion polypeptides
WO2007146968A2 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
RU2563343C2 (ru) * 2007-12-14 2015-09-20 Ново Нордиск А/С Антитела к человеческому nkg2d и их применения
CA2758751C (en) * 2009-04-14 2017-03-21 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
JP6002660B2 (ja) * 2010-04-15 2016-10-05 ジェネンテック， インコーポレイテッド 抗ユビキチン抗体及び使用方法
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
BR112014002716A2 (pt) * 2011-08-05 2017-06-13 Genentech Inc anticorpos anti-poliubiquitina e métodos de uso
WO2014179363A1 (en) * 2013-04-29 2014-11-06 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
SG10201913680PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
EP3218390A4 (en) * 2014-11-11 2018-11-21 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
CN107207600A (zh) * 2015-01-08 2017-09-26 协和发酵麒麟株式会社 与trailr2和psma结合的双特异性抗体
US20180318417A1 (en) * 2015-01-14 2018-11-08 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
AU2016219785B2 (en) * 2015-02-20 2021-10-28 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
WO2016135041A1 (en) * 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN107921090A (zh) * 2015-04-06 2018-04-17 苏伯多曼有限责任公司 含有从头结合结构域的多肽及其用途
US20200048345A1 (en) * 2015-12-28 2020-02-13 Innate Pharma Multispecific antigen binding proteins

Also Published As

Publication number Publication date
EP3579878A1 (en) 2019-12-18
US20200024353A1 (en) 2020-01-23
EP3579878A4 (en) 2020-11-18
IL268574A (en) 2019-09-26
JP2020507577A (ja) 2020-03-12
RU2019128204A (ru) 2021-03-10
RU2019128204A3 (ko) 2021-07-16
BR112019016553A2 (pt) 2020-03-31
CA3053275A1 (en) 2018-08-16
MX2019009541A (es) 2019-12-16
JP2022105121A (ja) 2022-07-12
WO2018148610A1 (en) 2018-08-16
CN110913902A (zh) 2020-03-24
AU2018217834A1 (en) 2019-08-22
KR20190120770A (ko) 2019-10-24

Similar Documents

Publication Publication Date Title
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16
SG11201907271PA (en) Proteins binding psma, nkg2d and cd16
SG11201907648XA (en) Proteins binding gd2, nkg2d and cd16
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201808821WA (en) Agonistic antibodies that bind human cd40 and uses thereof
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201900501RA (en) Cannabis composition
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201906468TA (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof